Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-007 in Healthy Geriatric Volunteers and Patients with Dementia
NCT02078310Phase 2Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Feb 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumateperone in Alzheimer's disease (AD) (4 arms), sponsored by Intra-Cellular Therapies. Primary endpoint: Number of participants with adverse events up to 7 days. Started Feb 2014; status: completed.
02
Drugs
lumateperone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02078310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078310.